brodalumab

Ligand id: 7540

Name: brodalumab

References
1. Chiricozzi A. (2014)
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Actas Dermosifiliogr105 Suppl 1: 9-20. [PMID:25398488]
2. Girolomoni G, Mrowietz U, Paul C. (2012)
Psoriasis: rationale for targeting interleukin-17.
Br. J. Dermatol.167 (4): 717-24. [PMID:22716185]
3. Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T et al.. (2012)
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
J. Allergy Clin. Immunol.130 (1): 145-54.e9. [PMID:22677045]
4. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A. (2014)
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis.
N. Engl. J. Med.370 (24): 2295-2306. [PMID:24918373]
5. Mullard A. (2017)
New plaque psoriasis approval carries suicide warning.
Nat Rev Drug Discov16 (3): 155. [PMID:28248935]
6. Russell CB, Rand H, Bigler J, Kerkof K, Timour M, Bautista E, Krueger JG, Salinger DH, Welcher AA, Martin DA. (2014)
Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
J. Immunol.192 (8): 3828-36. [PMID:24646743]
7. Tocker J, Mehlin C, Lim AC. (2010)
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto.
Patent number: US7767206. Assignee: Amgen Inc.. Priority date: 02/10/2006. Publication date: 03/08/2010.